anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aim 1. Environmental Scan of Health Communications Landscape. Using quantitative methods, examine the health communications landscape of younger (25-44 years old) and older (45-75 years old) adults living in rural communities. N=300 survey responses (n=150 from each age group) will be analyzed to determine the primary channels and sources of health-related information, quantify the extent to which these residents engage in family communications about cancer screening, and identify potential strategies for upward communications. Individual factors (i.e., CRC screening knowledge, health literacy, and numeracy) and specific facilitators of and barriers to upward communication about CRC screening will be also assessed.

Aim 2. Message Development and Refinement. Using qualitative methods, develop and evaluate intervention components to facilitate effective upward communications about CRC prevention and screening. To accomplish this aim, we will: 1) use findings from Aim 1 to design intervention content and materials that leverage relevant communication channels and strategies, and address barriers to upward communication and 2) conduct n=9 focus groups with adult children 25-44 years of age (n=3), CRC screening age-eligible adults, 45-75 years old (n=3), and adult child/parent dyads (n=3), to assess message acceptability and refine key content areas. We will iterate and modify intervention components based on feedback.

Aim 3. Preliminary Testing. Using a single arm, open-label, pre-test post-test design (n=15 adult child/parent dyads), assess the impact of a young adult-mediated intervention to increase CRC screening among a paired age-eligible family member (e.g., parent/grandparent). The focus of the intervention will be on changes in CRC screening awareness and intentions among the age-eligible adult, but we hypothesize that the young adult could benefit as well. Thus, in addition to assessing feasibility and acceptability, we will assess changes in 1) CRC screening intentions among the age-eligible adults and 2) CRC health literacy and awareness of screening guidelines among the younger adult participant.
PURPOSE:To obtain the titled suppressive agent comprising an aqueous solution containing scopolia extract and a salt having buffering action. CONSTITUTION:A suppressive agent for gastrointestinal peristalsis comprising an aqueous solution containing 0.01-1w/v% scopolia extract and 0.01-1w/v% inorganic or organic salt having buffering action (e.g. sodium metaphosphate, acidic sodium pyrophosphate, sodium phosphate, sodium citrate, etc.) as active ingredients. A dose of scopolia extract when the suppressive agent is used is 2-200mg/time, preferably 10-50mg/time. A saccharide such as white sugar, lactose, fructose, glucose, etc., sugaralcohol such as D-sorbitol, etc., are used as a water-soluble excipient. The suppressive agent has low side effects such as hydrodipsia, motor ataxia, etc., and made into a form to be readily administered and medicated with a relatively small amount of water. The suppressive agent has relatively immediate effects and continues the effects for 30-90min.
PROBLEM TO BE SOLVED: To obtain a cosmetic for washing skin which contains a specific metal salt of n N-acyl-L-glutamic acid as an active ingredient, has a strong foaming power, forms fine foam and gives skin fresh feeling without sliminess with high safety to skin. SOLUTION: This cosmetic contains a monomagnesium N-acyl-L-glutamate of the formula (RCO-is a residue of a fatty acid). The content of the glutamate of the formula is 0.1-30wt.%, preferably 3-25wt.%. An N-acyl-L-glutamic acid has a chemical structure that the amino group in the glutamic acid reacts with the carboxyl group in the fatty acid to form an amide bond. The fatty acid is desirably lauric acid or a mixture mainly comprising the same. The cosmetic for washing skin means body shampoo, skin cleansing foam, skin cleansing cream and the like.
Patients who are scheduled for gastric bypass (GBP), sleeve gastrectomy (SG), or simple caloric restriction with gastric banding (BND) or a very low calorie diet (VLCD) will be examined at baseline weight, and when 6-10% total body weight has been lost. We will measure insulin sensitivity with an intravenous glucose tolerance test, and fasting levels of hormones that regulate food intake and insulin sensitivity, such as ghrelin, peptide YY (PYY), glucagon-like peptide 1 (GLP1) and leptin. Fat mass and skeletal muscle mass will be measured by dual photon absorptiometry (DXA). We will also measure the hormonal and thermic response to food with a liquid test meal and energy expenditure by indirect calorimetry. This measures how many calories are burned at rest and the in response to food. Subjects with diabetes will continue to be studied with the same protocol on an annual basis out to 5 years in order to determine the rate of remission of diabetes and the durability of this effect as subjects tend to regain some body weight over time.

Subjects with diabetes will also be followed every three months for the first year after the initial weight loss for HbA1c and fasting glucose levels. The results of this study may lead to new understanding about changes in insulin sensitivity, body composition and hormonal profile, as well as changes in energy expenditure with weight loss after bariatric surgery or with simple caloric restriction. With this greater understanding, new treatments for obesity and diabetes, that do not require surgery, may be developed.
BACKGROUND: A two-way relationship exists between type 2 diabetes (T2DM) and human nonalcoholic steatohepatitis (NASH). Several diabetic NASH models have the disadvantages of long cycles or inconsistent with the actual incidence of human disease, which would be costly and time-consuming to investigate disease pathogenesis and develop drugs. Therefore, there is an urgent need to establish a diabetic NASH mouse model.
METHODS: The combination between Fructose-palmitate-cholesterol diet (FPC) and Streptozotocin (STZ) (FPC+STZ) was used to construct diabetic NASH mouse model. The in vivo effects of silencing acid-sensitive Ion Channel 1a (ASIC1a) were examined with an adeno-associated virus 9 (AAV9) carrying ASIC1a short hairpin RNA (shRNA) in FPC+STZ model.
RESULTS: The mice fed with FPC for 12 weeks had insulin resistance, hyperinsulinemia, lipid accumulation, and increased hepatic levels of inflammatory factors. However, it still did not develop remarkable liver fibrosis. Most interestingly, noticeable fibrotic scars were observed in the liver of mice from FPC+STZ group. Furthermore, insulin therapy significantly ameliorated FPC+STZ-induced NASH-related liver fibrosis, indicating that hyperglycemia is of great significance in NASH development and progression. Importantly, ASIC1a was found to be involved in the pathogenesis of diabetic NASH as demonstrated that silencing ASIC1a in HSCs significantly ameliorated FPC+STZ-induced NASH fibrosis. Mechanistically, ASIC1a interacted with Poly Adp-adenosine ribose polymerase (PARP1) to promote HSC activation by inducing autophagy.
CONCLUSION: A FPC diet combined with an injection of STZ induces a diabetic NASH mouse model in a shorter period. Targeting ASIC1a may provide a novel therapeutic target for the treatment of diabetic NASH.
1,164,808. Suppositories. MUNDIPHARMA A.G. 9 Nov., 1966, No. 50229/66. Heading A5B. [Also in Division C3] Pharmaceutical preparations comprise, as a suppository base, a compound consisting of a polymeric polycyclohexose moiety and a polyoxyethylene glycol moiety which are hydrogen-bonded together, and a pharmacologically active substance. The polyoxyethylene glycol preferably has a molecular weight of from 200 to 6000 and the polycyclohexose may be gum guar, pectin, algin, carboxymethylcellulose or a mixture thereof. The hydrogen-bonded compounds preferably contain from 5 to 40 per cent by weight of the ipolycyclohexose moiety and from 60 to 95 per cent by weight of the polyoxyethylene glycol moiety. Suitable pharmacologically active substances are antibiotics, antiseptic agents, germicides, contraceptive agents, hormones, steroids, analeptic agents, diuretic compounds, sedative agents, central nervous system stimulants, analgesic medications such as aspirin and choline salicylate, laxative and narcotic medications and cardiotonic agents.
Chronic sinus infections (chronic sinusitis or CRS) are common conditions that affect millions of Americans. While this is a common disorder, medical treatments for this condition vary a lot and little is known how and why different treatments work in some individuals and not in others. Some physicians commonly utilize a course of oral steroid therapy similar to treatment of inflammatory conditions including asthma and arthritis. Other physicians feel that oral steroids are not more effective than nasal steroid sprays in reducing inflammation and prefer prescribing nasal steroids. There is no conclusive data as to whether oral or sprayed nasal steroids are more effective in providing long-term benefit to patients. Nasal steroids are FDA approved to treat some types of chronic sinusitis but oral steroids are FDA approved medications that are used to treat inflammatory conditions but is not specifically indicated for chronic sinusitis and thus should be regarded as investigational drug. The purpose of this research study is to better understand whether orally administered steroids results in superior results when compared with nasally sprayed steroids. The investigators will compare patients with chronic sinusitis who are first treated with antibiotics and oral steroids, and compare them to chronic sinusitis patients who receive antibiotics and nasally sprayed steroid therapy.
1506953 Catamenial tampons PROCTER & GAMBLE CO 7 May 1975 [13 May 1974] 19106/75 Heading A5R  A medicated catamenial tampon 15, Fig. 2, comprises a resilient foam body 10 and a hydrophobic non-woven overwrap 11 which is permeable to vaginal fluids and carries stripes 12 of a therapeutically active agent for the control of vaginal disorders in a lubricant which is soluble in vaginal fluid and which has a melting point above normal vaginal temperature, i.e. 37C, but below 50C. The lubricant may comprise polyethylene glycol, polyethylene-4-sorbitan monostearate, polyoxyl 40 stearate, or mixtures thereof. The active agent may comprise nystatin, other examples being given in the Specification. The body preferably comprises polyurethane foam and, following compression and insertion of the tampon into the vagina, the tampon expands to conform to the vaginal wall, the overwrap being loose around the foam and being soft, flexible and biodegradable with small apertures therein. A withdrawal string 14 is provided. Inserters. A telescoping tuber type polyethylene inserter 17, Fig. 1, having inwardly tapering flexible segments at the leading end to form a normally closed, smooth leading end, is provided.
Indomethacin cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

The pharmacological activity of indomethacin in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.

### Hepatic Effects 

Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including indomethacin. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.

A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test values has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with indomethacin. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), indomethacin should be discontinued.

### Hematological Effects 

Anemia is sometimes seen in patients receiving NSAIDs, including indomethacin. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including indomethacin, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving indomethacin who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.

### Preexisting Asthma 

Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Since cross-reactivity, including bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, indomethacin should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
The invention discloses a normal-temperature preparation method for rheum franzenbachii munt. submicron powder, which comprises: slicing rheum franzenbachii munt. which is a Chinese medicine and drying the slices till the moisture content in the slices is less than or equal to 10 percent; grinding dry rheum franzenbachii munt. at normal temperature to obtain coarse powder with a particle size of 60 to 80 meshes; grinding obtained coarse powder in a rod mill, delivering the powder to a special bidirectional airflow sieving machine by wind to sieve the powder with a 500-mesh sieve, delivering undersize submicron powder with a particle size of less than or equal to 25 micrometers to a cyclonic material collection device by an air flow generated by a draft fan, and collecting finished rheum franzenbachii munt. submicron powder; and collecting oversize powder by a funnel and delivering the oversize powder to a rod mill by a pipe for secondary circular grinding. The method has the advantages that: the whole preparation process is carried out at normal temperature, and the need of low-temperature or special additional conditions are obviated; the particle size of the prepared finished medicine is less than or equal to 25 micrometers, and the cell wall breakage rate and bioavailability are improved greatly; and the used bidirectional airflow sieving machine simplifies the preparation process of the rheum franzenbachii munt. submicron powder, and makes the quality standards of Chinese medicine powder controllable.
The form is used in human and veterinary medicine. It is inthe form of antiglucocorticoid medicamentous preparation ofnonsteroid nature, with low toxicity and high efficiency for theregulation of the sensitivity of the cells of mammals to theactivity of the glucocorticoid hormones. With the intention ofselective suppression of the activity of the glucocorticoidhormones on the mammal cells a ferromone of insects of nonsteroidnature or its synthetic analogue or derivative is used being along-chain nonsaturated aliphatic alcohol, aldehyde or ester. Thelength of the carbon chain of each of the above elements is within10 to 21 atoms. To increase the therapeutical effect two or moreferromones and/or their synthetic analogues and derivatives areused selected according to the principle of an essentialdifference in the hydrophobia proportional to the lengths of thealiphatic hydrocarbon chains. The difference between the lengthsof the chains should be no less than five.4 claims
A personal item storage tray which includes a storage surface that incorporates a personal item identification, placement, retention, storage and removal apparatus or structure. One embodiment includes a substantially planar arrangement of depressions or recessed compartments designed to receive specific personal items such as, for example, eyeglasses, hearing aids and dentures. The compartments may be uniquely designed, shaped and marked to signal the uses of the compartment and to distinguish each compartment from the other to aid in visual identification and discrimination between the uses of each recessed compartment. The presence of items in the compartments is used to signal to the users of the tray that items are accounted for and not missing. The bottom surface of the tray includes a non-skid surface to avoid accidental or undesirable lateral movement. The tray is designed with a moldable or shapeable material. The tray has personal item inventory and management automation features and devices incorporated into its body to assist nursing staff or other users in accounting for personal items. Such inventory or missing item notification automation features includes a system having timers, sensors, and alerting signaling devices. These devices detect the presence of personal items within the tray storage areas and sound, signal or emit a missing item indication. The staff or other users of the tray are alerted to the necessity to search for a missing item when the tray signal system is activated.
OBJECTIVES: I. Determine the effect of nonmyeloablative chemotherapy followed by allogeneic peripheral blood stem cell transplantation on hematopoietic recovery in patients with hematologic malignancies. II. Determine the toxicities of this regimen in these patients. III. Determine the frequency of mixed hematopoietic chimerism in these patients after this therapy. IV. Determine the efficacy and toxicity of donor leukocyte infusions at relapse in these patients. V. Determine the response rates and survival of these patients after this therapy. VI. Determine the immune reconstitution of patients undergoing this therapy.

OUTLINE: Patients receive fludarabine IV over 30 minutes on days -9 to -5, cyclophosphamide IV over 1 hour on day -5, and antithymocyte globulin IV over 10 hours on days -5 to -2. Allogeneic peripheral blood stem cells are infused on day 0. Patients who achieve complete remission (CR) and then relapse or patients who achieve less than a CR before day 60 receive donor leukocyte infusions (DLI) over 30 minutes. DLI are repeated as necessary for persistent disease. Patients are followed at 1, 3, and 6 months, then at 1 and 2 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.
Life-threatening or fatal cardiovascular reactions including hypotension, shock, cardiac arrest have occurred with the parenteral administration of OMNIPAQUE. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Cardiac decompensation, serious arrhythmias, and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography.

Based upon clinical literature reported deaths from the administration of iodinated contrast agents range from 6.6 per million (0.00066%) to 1 in 10,000 (0.01%). Use the lowest necessary dose of OMNIPAQUE in patients with congestive heart failure and always have emergency resuscitation equipment and trained personnel available. Monitor all patients for severe cardiovascular reactions.
The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One 2-hour group session will be offered once a week for 12 weeks. In addition, 30 minutes of individual training will be provided weekly by an instructor.
There have been postmarketing reports of angioedema in patients during initial and chronic treatment with LYRICA. Specific symptoms included swelling of the face, mouth (tongue, lips, and gums), and neck (throat and larynx). There were reports of life-threatening angioedema with respiratory compromise requiring emergency treatment. Discontinue LYRICA CR immediately in patients with these symptoms.

Exercise caution when prescribing LYRICA CR to patients who have had a previous episode of angioedema. In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema.
The drink container with a heterogeneous composite or heterogeneous mixture/dispersing system consisting of a drinkable viscous food as dispersing agent and a uniform very finely distributed fine-grained pure loess/healing earth as disperse phase, comprises a filling opening and a discharge opening, which is locked with a screw cap, a crown cap or a closure formed to open and is formed to open by a drinking tube. The food is a drinkable honey or syrup and a drinkable yogurt, which is prepared with a fruit preparation and is a skimmed milk yogurt. The drink container with a heterogeneous composite/heterogeneous mixture/dispersing system consisting of a drinkable viscous food as dispersing agent and a uniform very finely distributed fine-grained pure loess/healing earth as disperse phase, comprises a filling opening and a discharge opening, which is locked with a screw cap, a crown cap or a closure formed to open and is formed to open by a drinking tube. The food is a drinkable honey or syrup and a drinkable yogurt, which is prepared with a fruit preparation and is a skimmed milk yogurt. The volume portion of the loess powder/healing earth is smaller than 10% of the total volume of the heterogeneous composite/heterogeneous mixture/dispersion system. An independent claim is included for a method for the production of the container with a heterogeneous composite/a heterogeneous mixture/dispersing system.
In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).